The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer

Abstract

Objectives: DR-70 is a newly developed immunoassay that detects fibrin degradation products in blood. To the best of our knowledge, no previous study has investigated the prognostic and predictive value of DR-70 in patients with advanced breast cancer. Methods: Seventy-four metastatic breast cancer patients and 35 healthy volunteers were enrolled prospectively. Blood samples were collected before and after the treatment, and PET-CT imaging was performed accordingly. Results: The median age was 54 (range 27-89) years. N=47 (63.5%) were luminal breast cancer, n=20 (27%) were HER2 type, and n=7 (9.5%) were TNBC. The medianDR-70 levels of patients and healthy volunteers were significantly differ- ent 0.91(0.22-10) and 0.39(0.22-0.93) (p<0.001), respectively. There was no correlation between pre-treatment DR-70 and CEA, CA15-3 levels (p=0.68, p=0.43), respectively. The basal value of DR70 was not significant in predicting survival (p=0.29). A level of 55 % and above decrease in the DR70 values before and after treatment was found to be a good prognostic factor. There was A significant correlation between DR70 response and disease control (p<0.001). Conclusion: DR70 response is a good predictive marker for response evaluation and a good marker for prognostication In patients with advanced breast cancer.